$CALC

CalciMedica, Inc. (CALC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001534133 false 0001534133 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2

Middleton Fred A purchased 248,972 indirectly-held shares of CalciMedica, Inc. (CALC) at $0.80 ($0.20M total) on 2026-06-25.

CalciMedica, Inc. (CALC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 d142943dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version CALCIMEDICA, INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “ Agreement ”) is made as of June 23, 2026 (the “ Effective Date ”), by and between CALCIMEDICA, INC. , a Delaware co

CalciMedica, Inc. (CALC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.3 4 d40651dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS

Jorey Chernett, a reporting person for CalciMedica, has filed an amended Schedule 13G/A, indicating that they no longer beneficially own any shares of the company's common stock as of May 19, 2026. This "exit filing" officially reports 0% ownership of the class. The amendment serves as a routine ownership update, though it does not detail the specifics of how or when the shares were disposed of.

CalciMedica (CALC) has filed an amendment to its annual report (10-K/A), detailing 2025 executive compensation, board governance, ownership stakes, and related-party transactions, as well as a $20.4 million private placement from 2024. The filing specifies executive pay, significant equity awards, and severance policies, with CEO A. Rachel Leheny receiving $895,410 in total compensation for 2025. It also updates information on major shareholders and outlines fees paid to the independent auditor.

CalciMedica (NASDAQ: CALC) has received two notices from Nasdaq for non-compliance, specifically for its market value of listed securities falling below $35 million and its common stock trading below the $1 minimum bid price for 30 consecutive business days. The company has 180 calendar days for each deficiency, until September 9, 2026, for market value and September 14, 2026, for bid price, to regain compliance through various alternatives, including a possible reverse stock split. Failure to do so could result in delisting from the Nasdaq Capital Market.